Table 1 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
收藏数据链接：
官方服务：
资源简介：
Baseline patient and disease characteristics (safety population).
创建时间：
2025-04-14
